Australia
Frontier biotechnology, natural bioactive discovery and translational research.
TASCAPについて
科学的な明確さのための地域フォーラム
新興科学を早すぎる確信に変えることなく、分野と市場をつなぐ独立した科学交流コンソーシアムです。
基本情報
アジア太平洋標的・精密アンチエイジング科学協会 · Targeted and Precision Anti-Aging Scientific Consortium Asia Pacific
- Full name
- Targeted and Precision Anti-Aging Scientific Consortium Asia Pacific
- Abbreviation
- TASCAP
- Nature
- A neutral, third-party international platform for academic and clinical-technology exchange, rooted in Asia Pacific and open to responsible global participation.
設立目的と科学的背景
As biotechnology and proactive health medicine accelerate, healthy-aging practice is moving beyond experience-led aesthetics and general maintenance toward measurable, mechanism-informed and longitudinal longevity medicine.
TASCAP convenes interdisciplinary researchers, university faculty, clinicians, leading R&D organisations, healthy-aging management institutions and frontier technology companies. Its central subject is targeted and precision anti-aging: defining the biological question, selecting an appropriate measurement, matching an intervention to a stated mechanism and following outcomes over time.
アジア太平洋4地域の補完的な強み
国・地域は英語名のアルファベット順（A–Z）で掲載。
China
Multi-omics data, large-scale research infrastructure and industrial extracellular-vesicle production, including Hong Kong, Macao and Taiwan.
Japan
Advanced clinical regenerative medicine, refined medical aesthetics, premium beauty care and service delivery.
Singapore
Sports medicine, modern clinical management and precision-health technology.
TRANSLATION
科学交流から臨床実装への架け橋
TASCAP links universities, clinics, research organisations and technology enterprises through multidisciplinary exchange, high-standard clinic evaluation and transparent evidence review. Longevity medicine and regenerative-medicine translation provide the common language; jurisdiction-specific clinical judgment, ethics and regulation remain essential.
精密ロンジェビティ管理ループ
The working model is designed to replace fragmented snapshots with a traceable cycle of baseline, targeted action, delivery and learning.
Baseline intelligence
Combine medical context with fit-for-purpose omics, biomarkers, wearables and a consent-based digital health record.
Targeted intervention
Define the objective, mechanism, evidence level, safety boundary and stop conditions for targeted extracellular-vesicle or regenerative approaches.
Regional delivery
Coordinate qualified institutional delivery, including appropriate Japanese clinical service pathways, under local professional and regulatory requirements.
365-day follow-up
Monitor selected signals longitudinally, document outcomes and adverse events, and repeat relevant assessments to refine—not predetermine—the next decision.
重点科学フロンティア
TASCAP follows fields that can sharpen measurement, targeting and longitudinal evaluation while keeping maturity of evidence visible.
Biological-age measurement
Epigenetic clocks, methylation patterns, telomere measures and multi-marker panels—with emphasis on analytical validity, repeatability and clinically meaningful change.
Cellular senescence & inflammaging
Mapping context-specific senescent-cell states, immune aging and chronic inflammation; senotherapeutics remain an active clinical-research field.
Mitochondria autophagy & proteostasis
Mechanisms that shape energy metabolism, cellular recycling and protein quality, assessed within the broader hallmarks-of-aging framework.
Multi-omics & systems biology
Integrating genomic, epigenomic, transcriptomic, proteomic, metabolomic and microbiome signals to identify subtypes and testable targets.
Regenerative medicine & extracellular vesicles
Source, identity, cargo, potency, targeting, manufacturing consistency and safety are evaluated before translational claims; much anti-aging evidence remains preclinical.
Lifestyle precision & digital phenotyping
Exercise, nutrition, sleep and recovery can be tracked with validated clinical measures and wearable signals to support individual longitudinal learning.
科学諮問委員会
The proposed board is organised around the science and clinical translation of targeted and precision anti-aging. Confirmed members, affiliations, roles and conflict disclosures will be published only after formal appointment.
01Targeted extracellular vesicles, regenerative medicine & biomanufacturing
02Multi-omics, biomarkers & biological-age measurement
03Longevity medicine, preventive medicine & clinical evaluation
04Sports medicine, exercise physiology & functional performance
05Medical aesthetics, dermatology & healthy-aging care
06Natural bioactives, nutrition & translational biotechnology
TASCAPの活動原則
Neutral exchange
Commercial participation does not purchase scientific conclusions or imply product endorsement.
Evidence discipline
Mechanistic, in-vitro, animal, human and real-world evidence are labelled as different levels.
Clinical responsibility
Educational exchange does not replace diagnosis, informed consent, qualified care or local regulatory review.
Longitudinal learning
A result is interpreted against baseline, method, biological variation and a pre-defined follow-up question.
Scientific scope notice: TASCAP discusses emerging science for education and professional exchange. No biomarker, clock, extracellular-vesicle product or regenerative intervention should be interpreted as proven to reverse human aging unless supported by appropriate regulatory status and robust clinical evidence.
主要な科学的基盤
Hallmarks of Aging: An Expanding Universe (Cell, 2023) ↗From Geroscience to Precision Geromedicine (Cell, 2025) ↗Cellular Senescence & Healthy Aging (NIA) ↗Small Extracellular Vesicles & Aging (Nature Aging, 2024) ↗Furber J · Systems Biology of Human Aging Network Model 2018 · Innovation in Aging ↗Systems Biology of Human Aging Network Model 2026 · Revised 2 June 2026 · Legendary Pharmaceuticals LLC ↗
ガバナンス、法的地位、役員、専門家任命は正式承認後にのみ公開します。本版では氏名や所属関係を創作していません。